PE wars to billion-dollar IPO dreams, hospital sector is fighting fit

Major private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition highlights strong investor confidence in India's healthcare sector. The industry is entering a new growth phase driven by increasing demand, a shortage of hospital beds, and a rise in specialized medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S3xQGYv
via IFTTT

Read More

Warburg, KKR, TPG among PE giants vying for 25% stake in Cloudnine

Global private equity giants, including Warburg Pincus and KKR, are vying for a 25% stake in India's largest maternity and pediatric hospital chain, Cloudnine. The deal is expected to value the company at approximately $1 billion, with existing investor True North exiting completely. Cloudnine reported revenues of ₹2,000 crore and EBITDA of ₹300 crore in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KIsAC3d
via IFTTT

Read More

Pharma exports to US seen muted this year

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are impacting shipments. US buyers are managing inventories more closely. A push for local manufacturing in the US also poses a challenge. This situation is creating caution among buyers for large forward orders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F3B7nNP
via IFTTT

Read More

Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility

Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines for global markets. US pharma giant MSD is the first major client. The plant signifies Aurobindo's expansion into the growing biologics and contract manufacturing sector. It is set to create over 1,500 jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EQ7zZbD
via IFTTT

Read More

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IhibuV6
via IFTTT

Read More

Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access to quality medicines for better patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTqrRtK
via IFTTT

Read More

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access for affected nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZVmTMeO
via IFTTT

Read More